ABS-752

ABS-752 (72 h) exerts cytotoxic/cytostatic activity in 13 of 19 tested HCC cell lines, reducing viability by at least 50%^[1].
ABS-752 (1-50 μM; 72 h) reduces viability in wild-type Hep3B cells, but has no effect on Hep3B GSPT1^G575N cells, demonstrating that GSPT1 degradation drives its cytotoxic activity^[1].
ABS-752 (0.1 nM-30 μM; 72 h) has viability-reducing activity in Hep3B cells that is dependent on VAP-1^[1].
ABS-752 (6 h, 24 h) potently degrades GSPT1 (DC₅₀=1 nM at 24 h), NEK7 (DC₅₀=9 nM at 24 h), CK1α (DC₅₀=35 nM at 24 h) in Hep3B cells, and SALL4 (DC₅₀=40 nM at 24 h) in Kelly cells, with GSPT1 as the primary target showing near-complete degradation at early time points^[1].
ABS-752 (0.1 μM; 6 h) preferentially degrades GSPT1, with greater degradation of NEK7 than CK1α^[1].
ABS-752 (1-10 μM) does not form a biochemical ternary complex with CRBN and GSPT1, NEK7, CK1α, or IKZF1, but shows recruitment activity with SALL4^[1].
ABS-752 (10 μM; 0-20 h) is converted to the aldehyde metabolite ABT-971 by recombinant mVAP-1^[1].
ABS-752 (125-2500 μM; 15 min) is oxidized by recombinant human VAP-1 with a K_m of 674 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.